Clinical trials
The latest chemistry news and research on clinical trials, including regulatory approval, trial safety and ethics, from the Royal Society of Chemistry's magazine, Chemistry World
-
BusinessArvinas and Pfizer seek a new home for protein degrader drug
Companies offer bifunctional cancer drug vepdegestrant to new partners after disappointing trial results
-
NewsCan a bowl of tomato soup a day keep the winter blues away?
Human trial to test whether gene-edited tomatoes can boost participants’ vitamin D levels
-
NewsAs AI-designed drug looks to pass final hurdle, will this tech change drug discovery forever?
AI-led drug for chronic lung disease set to enter phase 3 clinical trials, though experts remain divided on AI’s impact in pharma
-
OpinionIgnoring women’s health shouldn’t be an option
Developing therapies for conditions that predominantly affect women is a neglected, but enormous, opportunity
-
OpinionWomen are not just another confounding factor in drug development
Ignoring physiological differences between the sexes is indefensible
-
OpinionIn search of truth and rules
To codify and predict ever more complex phenomena is one of science’s great drivers
-
NewsFears grow over the future of mRNA vaccine research in the US
Researchers working on mRNA vaccines fear federal funding might be halted, with many looking to move projects abroad
-
BusinessEpigenetic editors enter clinical trials
New wave of precision medicines amplify or silence genes, without altering genetic code
-
OpinionRobots queuing up to fail
Claims of an AI revolution in drug discovery are missing the biggest problem
-
BusinessUS approves schizophrenia drug with new mode of action
Cobenfy promises to better address negative symptoms than existing antipsychotics
-
BusinessMDMA rejection poses questions for psychedelic drug trials
Decision prompts reflection over how psychotherapy is involved, regulating combination treatments and safeguarding patients
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
BusinessNew Covid-19 antiviral cuts symptoms by 1.5 days
Simnotrelvir already has emergency approval in China
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
-
BusinessPositive trial sets stage for therapeutic use of MDMA in US
Hallucinogen-assisted psychiatric treatment heads to regulators, amid cost and other concerns
-
BusinessAlzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
OpinionMay cause side effects
The dose makes the poison, but understanding unwanted drug interactions is complicated
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
NewsNew questions raised over Sputnik Covid vaccine results point to fraudulent practices
Analysis comparing Sputnik results with five other Covid vaccines finds phase 3 trial outcome is highly improbable
-
BusinessWhat is the future of Covid-19 pharmaceuticals?
Firms anticipate long-term markets for prevention and treatment